Phaseline

Companies › Guangzhou Novaken Pharm

Guangzhou Novaken Pharm: clinical trials, targets and expected readouts

2 active drug programs in 80 registered trials: 33 Phase 4, 19 Phase 3, 16 Phase 2, 12 Phase 1; Neurology, Cardiovascular, Gastroenterology, Genitourinary.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Dexmedetomidine
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 2Preoperative Sedation; Emergence Delirium; Laceration of Skin; Vaginal Delivery …–
XJN010 Nasal Spray
unclear mechanism
–Phase 2Parkinson Disease–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06712186DexmedetomidinePhase 1Elective Surgical PatientCardiovascularNov 2024
NCT06761092DexmedetomidinePhase 4Emergence DeliriumPsychiatryFeb 2025
NCT05849597DexmedetomidinePhase 3Intensive Care Unit DeliriumPsychiatryFeb 2025
NCT06702488DexmedetomidinePhase 1Mental DisorderOtherApr 2025
NCT06702488DexmedetomidinePhase 1Mental DisorderOtherApr 2025
NCT05934669DexmedetomidinePhase 4Laceration of SkinPsychiatryMay 2025
NCT06970626DexmedetomidinePhase 2Laparoscopic Sleeve GastrectomyOtherJun 2025
NCT06970678DexmedetomidinePhase 1Laparoscopic Sleeve Gastrectomy (LSG)OtherJun 2025
NCT06823349DexmedetomidinePhase 4Vaginal DeliveryOtherJun 2025
NCT07078201DexmedetomidinePhase 4Spinal Anesthesia DurationOtherJul 2025
NCT06252662DexmedetomidinePhase 4Breast CancerOncologyJul 2025
NCT06740903DexmedetomidinePhase 2Hemodynamics InstabilityGastroenterologyAug 2025
NCT07022821DexmedetomidinePhase 4Postoperative PainOtherAug 2025
NCT07034300DexmedetomidinePhase 4Post-operative PainOtherAug 2025
NCT07024043DexmedetomidinePhase 1Efficacy of Drugs in Pain ManagementOtherSep 2025
NCT06778811DexmedetomidinePhase 4Sleep Wake DisordersNeurologySep 2025
NCT05821972DexmedetomidinePhase 4SedationPsychiatryOct 2025
NCT06853431DexmedetomidinePhase 4Preoperative AnxietyPsychiatryNov 2025
NCT06087510DexmedetomidinePhase 4Scoliosis CorrectionGenitourinaryDec 2025
NCT05031026DexmedetomidinePhase 4Liver Transplant; ComplicationsOtherDec 2025
NCT06067958DexmedetomidinePhase 3Retinopathy of PrematurityOphthalmologyDec 2025
NCT03384563DexmedetomidinePhase 4Pediatric AnesthesiaOtherDec 2025
NCT06978192DexmedetomidinePhase 2Herpes Zoster (HZ)Infectious diseaseFeb 2026
NCT07350928DexmedetomidinePhase 3Breast CancerOncologyMar 2026
NCT07434206DexmedetomidinePhase 2Thyroid NeoplasmsOncologyMar 2026
NCT07168720DexmedetomidinePhase 2Preoperative SedationOtherMar 2026
NCT07156773XJN010 Nasal SprayPhase 2Parkinson DiseaseNeurologyMar 2026
NCT07080229DexmedetomidinePhase 3CataractCardiovascularApr 2026
NCT04801589DexmedetomidinePhase 3DeliriumPsychiatryApr 2026
NCT05640453DexmedetomidinePhase 4PregabalinCardiovascularMay 2026
NCT06979141DexmedetomidinePhase 3CoughOtherJun 2026
NCT06490731DexmedetomidinePhase 1Haemodynamic ReboundOtherJun 2026
NCT07590752DexmedetomidinePhase 2Pain, PostoperativePsychiatryJun 2026
NCT07611890DexmedetomidinePhase 4Laryngoscopic Stress ResponseOtherAug 2026
NCT06274333DexmedetomidinePhase 3Percutaneous Nephrolithotripsy (PCNL)OtherAug 2026
NCT07513935DexmedetomidinePhase 4Intraoperative AwarenessOtherSep 2026
NCT06943404DexmedetomidinePhase 2Acute Stress ReactionPsychiatrySep 2026
NCT03089905DexmedetomidinePhase 3AnesthesiaOtherOct 2026
NCT06958367DexmedetomidinePhase 1Aki After Ascending Aortic SurgeriesCardiovascularNov 2026
NCT06859892DexmedetomidinePhase 4AdultsCardiovascularNov 2026
NCT07519863DexmedetomidinePhase 2Emergence Delirium in Pediatric AnesthesiaOtherNov 2026
NCT07799311DexmedetomidinePhase 4Emergence Delirium, AnesthesiaPsychiatryNov 2026
NCT07462195DexmedetomidinePhase 4Thyroid DiseasesMetabolic and endocrineNov 2026
NCT07167316DexmedetomidinePhase 1The Role of the LC-NA System in Sleep RegulationOtherDec 2026
NCT07427446DexmedetomidinePhase 4Emergence DeliriumPsychiatryDec 2026
NCT04916197DexmedetomidinePhase 4Acute Ischemic StrokeNeurologyDec 2026
NCT05577962DexmedetomidinePhase 4Opioid-free AnesthesiaOtherDec 2026
NCT07878156DexmedetomidinePhase 3Posterior Fossa TumorOncologyDec 2026
NCT07767383DexmedetomidinePhase 4Knee Arthroscopic SurgeryOtherDec 2026
NCT07184801DexmedetomidinePhase 3Medical ThoracoscopyOtherDec 2026
NCT05383495DexmedetomidinePhase 3Laceration of SkinOtherDec 2026
NCT07550881DexmedetomidinePhase 2Acute Anxiety StatesPsychiatryDec 2026
NCT05303987DexmedetomidinePhase 2Obstructive Sleep ApneaRespiratoryJan 2027
NCT07389096DexmedetomidinePhase 4Opioid Free AnesthesiaOtherJan 2027
NCT07824817DexmedetomidinePhase 4Hemodynamic ResponseOtherFeb 2027
NCT07669012DexmedetomidinePhase 1Sedation and AnalgesiaOtherFeb 2027
NCT06335407DexmedetomidinePhase 1Alcohol Use Disorder (AUD)PsychiatryFeb 2027
NCT05712707DexmedetomidinePhase 1Opioid Use DisorderPsychiatryFeb 2027
NCT07308756DexmedetomidinePhase 4General AnesthesiaGenitourinaryMar 2027
NCT07392177DexmedetomidinePhase 2InsomniaPsychiatryMar 2027

The 60 nearest readouts of 80 trials; the rest in the app.

Targets

ADRA2A (1) ADRA2C (1) ADRA2B (1)

Companies with the same targets

BioXcel Therapeutics Teikoku Pharma USA Tarian Pharma Alcon Research Acer Therapeutics Santen SAS Pharmazz ARS Pharmaceuticals Terran Biosciences Australia Tecnoquimicas

Companies built like this

Teikoku Pharma USA Santen SAS Ascension Health Exciva Oticara Australia

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.